Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Post by righand99on Jan 15, 2016 9:34am
238 Views
Post# 24461358

Six people are in hospital....this might wake up some one...

Six people are in hospital....this might wake up some one...

Six people are in hospital and one brain dead after clinical trial for pot-based painkiller goes horribly wrong

A clinical trial in France has left one brain dead. It's believed to have been testing out a new cannabis-based painkiller.
Ernest Doroszuk/Postmedia Network A clinical trial in France has left one brain dead. It's believed to have been testing out a new cannabis-based painkiller.
  • Six people participating in a clinical trial for an experimental drug have been hospitalized after a “serious accident,” France’s Health Ministry said.
Damien Meye/AFP/Getty Images
Damien Meye/AFP/Getty ImagesThis file photo taken on March 29, 2011 shows a view of the hospital center (CHU) of Pontchaillou in Rennes. A "serious accident" during a French trial of a cannabis-based painkiller has left one person brain-dead and five hospitalized in Rennes.

One of the people is on life support and is considered brain dead, the ministry said in an e-mailed statement on Friday. The treatment is being developed by a European drugmaker, according to statement, which didn’t name the compound or its developer.

The participants in the early-stage trial were healthy volunteers and the drug was taken orally, the ministry said. The six volunteers were taken to the University Hospital of Rennes, and others who took the treatment are being recalled.

The nation’s drug safety agency ANSM plans to inspect the clinical trial site. Marisol Touraine, the French minister for health, said she will also travel to the hospital and hold a press briefing between 3 and 4 p.m. Paris time. Her office was informed of the incident on Thursday night.

The drug being tested was a cannabis-based painkiller, according to French daily Le Figaro.

A spokeswoman for the Health Ministry declined to give further details including the laboratory’s name. The Paris prosecutor’s spokeswoman Agnes Thibaut-Lecuivre wasn’t immediately available for comment. Press officers at the ANSM and at the Rennes hospital declined to comment.


Bullboard Posts